Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 1397Neoplasms 1129Prostatic Neoplasms 744Lung Neoplasms 619Colorectal Neoplasms 596Carcinoma, Non-Small-Cell Lung 569Carcinoma, Hepatocellular 413Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 398Stomach Neoplasms 355Multiple Myeloma 326Brain Neoplasms 311Ovarian Neoplasms 309Head and Neck Neoplasms 289Neoplasm Metastasis 273Precursor Cell Lymphoblastic Leukemia-Lymphoma 260Rectal Neoplasms 253Uterine Cervical Neoplasms 248Recurrence 248Melanoma 242Esophageal Neoplasms 237Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Lymphoma 213Sarcoma 207Urinary Bladder Neoplasms 192Colonic Neoplasms 192Glioma 191Triple Negative Breast Neoplasms 188Hematologic Neoplasms 183

Interventions

aumolertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × OTHER × Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor × Clear all
NCT04216121 2024-07-01

LAT-FLOSI

Universitaire Ziekenhuizen KU Leuven

Recruiting
39 enrolled
Thoracic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

NCT06102928 2023-10-26

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Kunming Medical University

Phase NA Recruiting
30 enrolled
Thoracic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡